OTCMKTS:MDNAF FY2027 EPS Estimate Raised by HC Wainwright

Medicenna Therapeutics Corp. (OTCMKTS:MDNAF) – Equities researchers at HC Wainwright increased their FY2027 earnings per share estimates for shares of Medicenna Therapeutics in a report released on Thursday, August 20th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.15) per share for the year, up from their prior estimate of ($0.17). The consensus estimate for Medicenna Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Medicenna Therapeutics’ FY2028 earnings at ($0.14) EPS, FY2029 earnings at ($0.12) EPS and FY2030 earnings at $0.10 EPS.

Medicenna Therapeutics (OTCMKTS:MDNAF) last announced its quarterly earnings data on Thursday, June 25th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05).

Medicenna Therapeutics Trading Up 7.7%

OTCMKTS:MDNAF opened at $0.31 on Monday. The stock has a 50-day moving average price of $0.27 and a 200 day moving average price of $0.41. The stock has a market capitalization of $28.93 million, a P/E ratio of -1.96 and a beta of 1.78. Medicenna Therapeutics has a 12-month low of $0.23 and a 12-month high of $1.43.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.